OncoMatch/Clinical Trials/NCT07081646
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Is NCT07081646 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies AZD0120 for relapsed al amyloidosis.
Treatment: AZD0120 — Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Disease stage
Excluded: Stage MAYO STAGE IIIB AL AMYLOIDOSIS
Measurable hematologic disease: dFLC > 20 mg/L or serum M-protein > 5g/L
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-plasma cell-directed therapy
Relapsed or refractory disease with a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
Cannot have received: CAR-T cell therapy
Prior CAR T cell therapy directed at any target
Cannot have received: BCMA-targeting therapy
Prior BCMA-targeting therapy
Lab requirements
Cardiac function
NYHA class III or IV excluded; systolic blood pressure <100mmHg excluded; oxygen saturation <95% on room air excluded
Oxygen saturation < 95% on room air; Systolic blood pressure <100mmHg; NYHA class III or IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Phoenix, Arizona
- Research Site · San Francisco, California
- Research Site · Tampa, Florida
- Research Site · Boston, Massachusetts
- Research Site · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07081646 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, BCMA-targeting therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages